ClinicalTrials.gg
Not yet recruitingNCT07946445Updated Nov 18, 2026

Assessment of Patient Radiation Exposure and Development of Diagnostic Reference Levels(DRLs) Standards for Endoscopic Retrograde Cholangiopancreatography (ERCP).

An observational study in Choledocholithiasis, Biliary Stricture and Chronic Pancreatitis, sponsored by Institute of Liver and Biliary Sciences, India. Not yet recruiting. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Institute of Liver and Biliary Sciences, India · Observational

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
150
Sex
All
01

Study summary

ERCP is a fluoroscopy procedures are associated with significant radiation exposure to patients. Radiation exposure is associated with adverse effects both short term and long term which might negatively impact the quality of life of the patient. The effects of radiation maybe deterministic or stochastic the effects may range from mild such as skin irritation to long term effects such as cancer. Hence there is a need to limit the dosage of radiation exposed to the patient. Therefore, there is a need to establish standard reference levels. Radiation is measured in Dose Area Product (DAP), Effective dose (ED), Reference air Kerma (Ka,r). The radiation exposure is measured for the patients undergoing ERCP from January 2023 to Dec 2025 will be collected. DRLs will be calculated for these metrics. DRL is 3rd quartile of the measured values. The dosage of radiation which the patient receives depends on several factors such as patients BMI, position, complexity of the procedure and several other factors. As a secondary objective several factors affecting the radiation exposure is also noted.

02

Conditions studied

  • Choledocholithiasis
  • Biliary Stricture
  • Chronic Pancreatitis
  • Periampullary Carcinoma
  • Cholangiocar.- Intra/Extrahepatic
  • Primary Sclerosing Cholangitis
  • Necrotizing Pancreatitis
  • Hepatocellular Carcinoma
  • Post Cholecystectomy
  • Pancreatic Duct Stricture
03

In context

Choledocholithiasis

109 studies on the registry are indexed under Choledocholithiasis; 24 are open to participants now.

This study's planned enrollment of 150 is below the median of 200 across 31 observational studies indexed under Choledocholithiasis.

Browse Choledocholithiasis studies →

Lead sponsor

Institute of Liver and Biliary Sciences, India is the lead sponsor of 303 studies on the registry; 88 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All consecutive in-patients and out-patients undergoing ERCP .

Eligibility criteria

Inclusion Criteria: • Patients Undergoing ERCP -

Exclusion Criteria: Patients with missing dosimetry data

-

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
150 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Estimate the distribution of total radiation dose (median, IQR, 75th percentile) reflected by DAP (Gy·cm²) for ERCP and propose local DRLs.

    Time frame: Day 0

Secondary outcomes

  1. - Estimation of Diagnostic reference (DRLs) -(median, IQR, 75th percentile)for ERCP procedures for Ka,r (in mGy) , FT (in min),ED(in mSv).

    Time frame: Day 0

  2. - Patient's fluoroscopy time (in min), reference air-kerma (in mGy), and number of acquisitions(n) will be measured

    Time frame: Day 0

  3. - Correlation of DAP and Ka,r with ASGE complexity grade, HOUSE grading, Stanford fluoroscopy complexity scores will be done using Spearman rank correlation coeffecient

    Time frame: Day 0

  4. - Track proportion of cases exceeding candidate DRLs or published reference values to guide procedure optimization.

    Time frame: Day 0

  5. Multivariate regression will be used for correlation of procedure indication, BMI(kg/m²), prior sphincterotomy(yes/no), trainee involvement (yes/no), collimation(yes/no), and image acquisitions with DAP(Gy·cm²) and Ka,r (in mGy)

    Time frame: Day 0

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Nov 2026, 0 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2026
First posted
Nov 18, 2026
StartEst.
Nov 16, 2026
Primary completionEst.
Nov 30, 2026
CompletionEst.
Nov 30, 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07946445
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Nov 16, 2026 (estimated)
Primary completion
Nov 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Nov 18, 2026

Study contacts

Settipally Vinay kumar, M.D
Contact
settipallyvsk@gmail.com
9848883993 ext. 91
Vikram Bhatia, D.M
Contact
vikrambhatiadr@gmail.com
9818014864 ext. 91

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion